ARCHIVES

Upton Promises “Minimal Disruption” As Result of Changes; Centers Program Probably To Move

This article is from The Cancer Letter archive.

Vol. 04 No. 03 | January 20, 1978

Download PDF Visit The Full Archive

Related Articles

Revlimid Plus Steroid Effective In Clinical Trial

November 30, 2007

ODAC Recommends Iressa Approval As Third-Line Lung Cancer Treatment

September 27, 2002

Panel Says Tamoxifen Remains Standard for Preventing Breast Cancer

May 24, 2002

In Brief: NCI Seeks Better Ways to Make Available Fresh Tissue; Iverson Heads Cancer Control Science

October 5, 1984

Also in this issue: ODAC Votes To Strip Breast Cancer Indication From Avastin

July 23, 2010

DCBD Board Rejects Breast Cancer Multiple Markers Concept Proposal

November 4, 1983